OCUGEN, INC. Repayments of Debt
OCUGEN, INC. (OCGN) reported Repayments of Debt of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2022-02-28
- OCUGEN, INC. repayments of debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. repayments of debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. repayments of debt for the quarter ending 2020-12-31 was $1.26M.
- OCUGEN, INC. repayments of debt for the quarter ending 2020-09-30 was $3.22M.
- OCUGEN, INC. repayments of debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- OCUGEN, INC. repayments of debt for fiscal 2020 was $5.63M, a 6.33% increase from fiscal 2019.
- OCUGEN, INC. repayments of debt for fiscal 2019 was $5.29M.
- OCUGEN, INC. repayments of debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month | Repayments of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | ||||
| 2020-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.49M derived: sum of 2 quarters · filed 2022-02-28 | $5.63M 10-K · filed 2022-02-28 | ||
| 2020-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.36M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $1.14M 10-Q · filed 2021-08-06 | ||||
| 2019-12-31 | $5.29M 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$178.00K derived: sum of 2 quarters · filed 2020-03-27 | -$133.00K derived: sum of 3 quarters · filed 2020-03-27 | $0.00 10-K · filed 2020-03-27 | $178.00K 10-K · filed 2019-03-22 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $45.00K derived: sum of 2 quarters · filed 2019-08-09 | $178.00K 10-Q · filed 2018-11-08 | $324.00K derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $178.00K 10-Q · filed 2019-08-09 | $324.00K derived: sum of 3 quarters · filed 2019-08-09 | $470.00K derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-03-31 | $133.00K 10-Q · filed 2019-05-15 | $279.00K derived: sum of 2 quarters · filed 2019-05-15 | $425.00K derived: sum of 3 quarters · filed 2019-05-15 | $570.00K derived: sum of 4 quarters · filed 2019-05-15 | |
| 2017-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $292.00K derived: sum of 2 quarters · filed 2019-03-22 | $437.00K derived: sum of 3 quarters · filed 2019-03-22 | $583.00K 10-K · filed 2019-03-22 | |
| 2017-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $291.00K derived: sum of 2 quarters · filed 2018-11-08 | $437.00K 10-Q · filed 2018-11-08 | $583.00K derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $291.00K 10-Q · filed 2018-08-09 | $437.00K derived: sum of 3 quarters · filed 2018-08-09 | $583.00K derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | $146.00K 10-Q · filed 2018-05-10 | $292.00K derived: sum of 2 quarters · filed 2018-05-10 | $438.00K derived: sum of 3 quarters · filed 2018-05-10 | $583.00K derived: sum of 4 quarters · filed 2018-05-10 | |
| 2016-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $292.00K derived: sum of 2 quarters · filed 2018-03-15 | $437.00K derived: sum of 3 quarters · filed 2018-03-15 | $583.00K 10-K · filed 2018-03-15 | |
| 2016-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $291.00K derived: sum of 2 quarters · filed 2017-11-09 | $437.00K 10-Q · filed 2017-11-09 | $583.00K derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $291.00K 10-Q · filed 2017-08-10 | $437.00K derived: sum of 3 quarters · filed 2017-08-10 | $583.00K derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-03-31 | $146.00K 10-Q · filed 2017-05-11 | $292.00K derived: sum of 2 quarters · filed 2017-05-11 | $438.00K derived: sum of 3 quarters · filed 2017-05-11 | $539.00K derived: sum of 4 quarters · filed 2017-05-11 | |
| 2015-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $292.00K derived: sum of 2 quarters · filed 2017-03-16 | $393.00K derived: sum of 3 quarters · filed 2017-03-16 | $406.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $247.00K derived: sum of 2 quarters · filed 2016-11-10 | $260.00K 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $114.00K 10-Q · filed 2016-08-11 | |||
| 2015-03-31 | $13.00K 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |